IONIS PHARMACEUTICALS INC IONS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
1.12
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $943.7M | -$381.4M | — | -$320.0M | $489.1M |
| 2024 | $705.1M | -$453.9M | — | -$546.2M | $588.4M |
| 2023 | $787.6M | -$366.3M | — | -$331.3M | $386.7M |
| 2022 | $587.4M | -$269.7M | — | -$290.1M | $572.9M |
| 2021 | $810.5M | -$28.6M | — | $18.8M | $771.7M |
| 2020 | $729.3M | -$444.3M | — | $772,000 | $743.3M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.12 (grey)
- Working capital / assets 0.627
- Retained earnings / assets -0.747
- EBIT / assets -0.108
- Equity / liabilities 0.161
Source: SEC EDGAR filings · CIK 0000874015 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.